The First Affiliated Hospital of Guangxi Medical University

Nanning 530021

11 studies enrolling now · 16 studies all time

What they study most

Acute Myeloid Leukemia, Acute Myocardial Infarction, Beta-Thalassemia, Crohn Disease, EGFR Exon 19 Deletion, EGFR L858R, Focal Segmental Glomerulosclerosis, Heart Failure, Leukemia, Leukemia, Myeloid, Acute, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Nonsquamous Non-Small Cell Lung Cancer

Studies at this site

• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia — Recruiting now
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — Recruiting now
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission — Recruiting now
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) — Running, not enrolling
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy — Running, not enrolling